# US 2026/0090539 A1 · Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0090539 A1
- Document ID: US20260090539A1
- Status: Published application
- Kind: A1
- Application number: 19/316,417
- Filed: 2025-09-02
- Published: 2026-04-02
- Earliest claimed: 2020-09-24
- Assignees: Everest Medical Innovation GmbH; Regents of the University of Minnesota
- Applicants: Everest Medical Innovation GmbH; Regents of the University of Minnesota
- Inventors: Franz Schmidlin; John Bischof; Paul A. Iaizzo; Qi Shao; Pegah Ranjbartehrani; David A. Ramirez
- Web page: https://patentgrep.com/patent/US20260090539A1

## CPC

- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A01N 1/128: Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
- A61B 5/388: Nerve conduction study, e.g. detecting action potential of peripheral nerves
- A61B 18/02: by cooling, e.g. cryogenic techniques
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/08: of the prostate
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61B 5/4381: {Prostate evaluation or disorder diagnosis}
- A61B 2018/00547: {Prostate}
- A61B 2018/00577: {Ablation}
- A61B 2018/00839: {Bioelectrical parameters, e.g. ECG, EEG}
- A61B 2018/0088: {Vibration}
- A61B 2018/0293: {using an instrument interstitially inserted into the body, e.g. needle}
- A61B 2090/378: {using ultrasound}
- A61B 2505/05: Surgical care
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A cryoprotective composition configured to be applied during cryotreatment of a patient includes at least one biodegradable and/or bioerodible fluid agent and at least one non-toxic cryoprotectant agent. A therapeutically effective amount of the cryoprotective composition deposited in a body space of the patient in proximity to the cryotreatment remains within at least a portion of the body space for a duration of the cryotreatment. At least a portion of a body tissue proximate to the body space is viable after the cryotreatment. A method of protecting a surgical site during prostate cryosurgery is also provided. The method includes injecting a therapeutically effective amount of the cryoprotective composition into the body space, wherein the body space is a periprostatic space of a patient.

## Claims

### Claim 1

(canceled)

### Claim 2

An injectable cryoprotective composition for injection into body tissue and/or body space, the cryoprotective composition comprising:
a polysaccharide gel or polysaccharide thickening agent;
a sugar cryoprotectant agent; and
a sulfoxide.

### Claim 3 (depends on 2)

The cryoprotective composition of claim 2, wherein the polysaccharide gel or polysaccharide thickening agent has a viscosity at about 20° C. to about 25° C. suitable to be ejected from a needle cannula into the body tissue.

### Claim 4 (depends on 2)

The cryoprotective composition of claim 2, wherein the polysaccharide gel or polysaccharide thickening agent remains flowable at a temperature of negative 10° C.

### Claim 5 (depends on 2)

The cryoprotective composition of claim 2, wherein the cryoprotective composition is configured to be deposited to the body tissue and/or body space during a cryosurgical procedure.

### Claim 6 (depends on 5)

The cryoprotective composition of claim 5, wherein the cryosurgical procedure comprises a procedure for treatment of cardiac arrhythmia.

### Claim 7 (depends on 5)

The cryoprotective composition of claim 5, wherein the cryosurgical procedure comprises ablation of aberrant nerves in proximity to a pulmonary artery and/or ablation of one or more of the following tumors: tumor(s) and/or lesions around an eye or eye orbit, esophageal tumor(s), skin tumor(s), pancreatic tumor(s), liver tumor(s), or brain tumor(s).

### Claim 8 (depends on 5)

The cryoprotective composition of claim 5, wherein the cryosurgical procedure comprises a procedure for treatment of chronic pain caused by trigeminal neuralgia.

### Claim 9 (depends on 2)

The cryoprotective composition of claim 2, wherein the polysaccharide gel or polysaccharide thickening agent comprises hydroxyethyl cellulose.

### Claim 10 (depends on 2)

The cryoprotective composition of claim 2, wherein the polysaccharide gel or polysaccharide thickening agent comprises from about 1 weight percent to about 10 weight percent of the cryoprotective composition.

### Claim 11 (depends on 2)

The cryoprotective composition of claim 2, wherein the sugar cryoprotectant agent comprises monosaccharides and/or disaccharides.

### Claim 12 (depends on 2)

The cryoprotective composition of claim 2, wherein the sugar cryoprotectant agent comprises at least one of glucose, galactose, lactose, fructose, sucrose, trehalose, raffinose, mannitol, and/or sorbitol.

### Claim 13 (depends on 2)

The cryoprotective composition of claim 2, wherein the sugar cryoprotectant agent comprises trehalose.

### Claim 14 (depends on 2)

The cryoprotective composition of claim 2, wherein the sugar cryoprotective agent comprises from about 5 weight percent to about 10 weight percent of the cryoprotective composition.

### Claim 15 (depends on 2)

The cryoprotective composition of claim 2, wherein the sulfoxide comprises Dimethyl sulfoxide (DMSO).

### Claim 16 (depends on 2)

The cryoprotective composition of claim 2, wherein the sulfoxide comprises from about 1 weight percent to about 5 weight percent of the composition.

### Claim 17 (depends on 2)

The cryoprotective composition of claim 2, wherein:
the polysaccharide gel or thickening agent comprises from about 1 weight percent to about 10 weight percent of the cryoprotective composition,
the sugar cryoprotectant agent comprises from about 5 weight percent to about 10 weight percent of the cryoprotective composition, and
the sulfoxide comprises about 1 weight percent to about 5 weight percent of the cryoprotective composition.

### Claim 18 (depends on 2)

The cryoprotective composition of claim 2, wherein the cryoprotective composition inhibits freezing and/or crystallization of the body tissue when cryotherapy agents are used in proximity to the body tissue.

### Claim 19

A topical protective composition configured to be applied to skin, the protective composition comprising:
a polysaccharide gel or polysaccharide thickening agent;
a sugar cryoprotectant agent; and
a sulfoxide.

### Claim 20 (depends on 19)

The topical protective composition of claim 19, wherein the topical protective composition is configured to protect the skin from damage caused by environmental conditions and does not cause substantial damage to the skin.

### Claim 21 (depends on 19)

The topical protective composition of claim 19, wherein:
the polysaccharide gel or thickening agent comprises from about 1 weight percent to about 10 weight percent of the topical protective composition,
the sugar cryoprotectant agent comprises from about 5 weight percent to about 10 weight percent of the topical protective composition, and
the sulfoxide comprises about 1 weight percent to about 5 weight percent of the topical protective composition.
